Barker-Haliski Lab

University of Washington

PHARMACOLOGY

Seattle · United States

NIH-funded
Rate this labNo reviews yet — be the first.

Research focus

NIH R01 · 2024

Impact of Chronic Seizures on Neuropsychiatric Comorbidities in AD-Associated Models

Abstract: Autosomal dominant early-onset Alzheimer's disease (ADEOAD) is associated with numerous genetic mutations, including those in amyloid precursor protein (APP), and presenilin (PSEN) 1 and 2 genes. Growing evidence indicates that patients with AD often experience undiagnosed focal seizures. Indeed, over 30% of AD patients with the most common PSEN2 gene variant (N141I) report seizures and patients with APP duplication have a similarly high incidence of reported seizures, suggesting an unexplored role of hyperexcitability in the pathophysiology of AD. Both epilepsy and AD are associated with numerous neuropsychiatric comorbidities. Limited clinical evidence suggests that AD patients…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.

Reviews

← All labs at University of Washington